Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Open-Label, Single-Arm, Multi Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma

Next Previous
Trial Profile

Phase 2, Open-Label, Single-Arm, Multi Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trebananib (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Amgen

Most Recent Events

  • 12 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
  • 25 Jun 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2015 to 1 Jul 2015.
  • 22 Apr 2014 Planned end date changed from 1 Jun 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top